Limits...
Targeting anti-inflammatory treatment can ameliorate injury-induced neuropathic pain.

Iwatsuki K, Arai T, Ota H, Kato S, Natsume T, Kurimoto S, Yamamoto M, Hirata H - PLoS ONE (2013)

Bottom Line: Etanercept treatment improved recovery of motor nerve conduction velocity, muscle weight loss, and sciatic functional index.Etanercept reduced expression of interleukin-6 and monocyte chemotactic and activating factor-1 at the crushed sciatic nerve.Etanercept does not impede the onset or progression of Wallerian degeneration, but optimizes the involvement of macrophages and the secretion of inflammatory mediators.

View Article: PubMed Central - PubMed

Affiliation: Department of Hand Surgery, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya, Japan. kiwatsuki@med.nagoya-u.ac.jp

ABSTRACT
Tumor necrosis factor-α plays important roles in immune system development, immune response regulation, and T-cell-mediated tissue injury. The present study assessed the net value of anti-tumor necrosis factor-α treatment in terms of functional recovery and inhibition of hypersensitivity after peripheral nerve crush injury. We created a right sciatic nerve crush injury model using a Sugita aneurysm clip. Animals were separated into 3 groups: the first group received only a skin incision; the second group received nerve crush injury and intraperitoneal vehicle injection; and the third group received nerve crush injury and intraperitoneal etanercept (6 mg/kg). Etanercept treatment improved recovery of motor nerve conduction velocity, muscle weight loss, and sciatic functional index. Plantar thermal and von Frey mechanical withdrawal thresholds recovered faster in the etanercept group than in the control group. On day 7 after crush injury, the numbers of ED-1-positive cells in crushed nerves of the control and etanercept groups were increased compared to that in the sham-treated group. After 21 days, ED-1-positive cells had nearly disappeared from the etanercept group. Etanercept reduced expression of interleukin-6 and monocyte chemotactic and activating factor-1 at the crushed sciatic nerve. These findings demonstrate the utility of etanercept, in terms of both enhancing functional recovery and suppressing hypersensitivity after nerve crush. Etanercept does not impede the onset or progression of Wallerian degeneration, but optimizes the involvement of macrophages and the secretion of inflammatory mediators.

Show MeSH

Related in: MedlinePlus

Electrophysiological evaluation after nerve crush injury.Motor nerve conduction velocity of the tibialis anterior muscle was significantly longer in the control group than in the etanercept and sham groups at 21 days post-crush injury (**p<0.01; *p<0.05).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3585184&req=5

pone-0057721-g001: Electrophysiological evaluation after nerve crush injury.Motor nerve conduction velocity of the tibialis anterior muscle was significantly longer in the control group than in the etanercept and sham groups at 21 days post-crush injury (**p<0.01; *p<0.05).

Mentions: On day 7, MCVs were not evoked for either the control group or the etanercept group. The results of electrophysiological assessments on days 21 and 35 after crush injury are shown in Figure 1. On day 21, MCVs were significantly slower for the control and etanercept groups than for the sham group, and MCV for the control group was significantly slower than that of the etanercept group. On day 35, MCV of the control group also recovered and significant differences were no longer evident between control and etanercept groups.


Targeting anti-inflammatory treatment can ameliorate injury-induced neuropathic pain.

Iwatsuki K, Arai T, Ota H, Kato S, Natsume T, Kurimoto S, Yamamoto M, Hirata H - PLoS ONE (2013)

Electrophysiological evaluation after nerve crush injury.Motor nerve conduction velocity of the tibialis anterior muscle was significantly longer in the control group than in the etanercept and sham groups at 21 days post-crush injury (**p<0.01; *p<0.05).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3585184&req=5

pone-0057721-g001: Electrophysiological evaluation after nerve crush injury.Motor nerve conduction velocity of the tibialis anterior muscle was significantly longer in the control group than in the etanercept and sham groups at 21 days post-crush injury (**p<0.01; *p<0.05).
Mentions: On day 7, MCVs were not evoked for either the control group or the etanercept group. The results of electrophysiological assessments on days 21 and 35 after crush injury are shown in Figure 1. On day 21, MCVs were significantly slower for the control and etanercept groups than for the sham group, and MCV for the control group was significantly slower than that of the etanercept group. On day 35, MCV of the control group also recovered and significant differences were no longer evident between control and etanercept groups.

Bottom Line: Etanercept treatment improved recovery of motor nerve conduction velocity, muscle weight loss, and sciatic functional index.Etanercept reduced expression of interleukin-6 and monocyte chemotactic and activating factor-1 at the crushed sciatic nerve.Etanercept does not impede the onset or progression of Wallerian degeneration, but optimizes the involvement of macrophages and the secretion of inflammatory mediators.

View Article: PubMed Central - PubMed

Affiliation: Department of Hand Surgery, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya, Japan. kiwatsuki@med.nagoya-u.ac.jp

ABSTRACT
Tumor necrosis factor-α plays important roles in immune system development, immune response regulation, and T-cell-mediated tissue injury. The present study assessed the net value of anti-tumor necrosis factor-α treatment in terms of functional recovery and inhibition of hypersensitivity after peripheral nerve crush injury. We created a right sciatic nerve crush injury model using a Sugita aneurysm clip. Animals were separated into 3 groups: the first group received only a skin incision; the second group received nerve crush injury and intraperitoneal vehicle injection; and the third group received nerve crush injury and intraperitoneal etanercept (6 mg/kg). Etanercept treatment improved recovery of motor nerve conduction velocity, muscle weight loss, and sciatic functional index. Plantar thermal and von Frey mechanical withdrawal thresholds recovered faster in the etanercept group than in the control group. On day 7 after crush injury, the numbers of ED-1-positive cells in crushed nerves of the control and etanercept groups were increased compared to that in the sham-treated group. After 21 days, ED-1-positive cells had nearly disappeared from the etanercept group. Etanercept reduced expression of interleukin-6 and monocyte chemotactic and activating factor-1 at the crushed sciatic nerve. These findings demonstrate the utility of etanercept, in terms of both enhancing functional recovery and suppressing hypersensitivity after nerve crush. Etanercept does not impede the onset or progression of Wallerian degeneration, but optimizes the involvement of macrophages and the secretion of inflammatory mediators.

Show MeSH
Related in: MedlinePlus